Article Drug pipeline

From Diabetes to Breast Cancer: Promise, Uncertainty, and the Case for Prospective Trials of GLP-1 Receptor Agonists

GLP-1 receptor agonists have transformed the treatment of type 2 diabetes and obesity. Now, researchers are exploring a new question: Could these medications also play a…

By Richa Madurkar

Article Drug pipeline

Managed Care Implications of Fixed-Duration Lenalidomide Maintenance in Multiple Myeloma (MM)

Is Shorter Duration Therapy Less Effective Than Indefinite Maintenance? The phase 3 ENDURANCE (E1A11) trial provides compelling evidence regarding the duration of lenalidomide maintenance in patients…

By Melissa Pozotrigo

Article Drug pipeline

The End of “Undruggable?”: Why RASolute-302 May Mark the Beginning of the Pan-RAS Era

The phase 3 RASolute-302 trial marks a potential turning point in oncology, demonstrating that pan-RAS inhibition with daraxonrasib may significantly improve survival in metastatic pancreatic cancer.…

By Corey Wise

Article Drug pipeline

Translating ASCO 2026: What Matters Most for Managed Care

ASCO 2026, the largest oncology conference in the world, featured groundbreaking clinical trial results expected to transform standards of care (SoC) in oncology. For payors, staying…

By Richa Madurkar

Article Drug pipeline

Innovations in Bladder Cancer Therapy: Implications for Managed Care

The treatment landscape for bladder cancer is rapidly evolving. Additional therapeutic options have been recently approved or are in the pipeline for patients in both non-muscle…

By Adam Leikensohn and Richa Madurkar

Article Drug pipeline

Front-Line Covalent BTK Inhibitor + Venetoclax ± Obinutuzumab: A New Triple Threat?

Emerging front-line chronic lymphocytic leukemia (CLL) treatment options combine covalent BTK inhibitors with venetoclax and obinutuzumab, prompting new considerations around clinical benefit, risk, and cost compared…

By Richa Madurkar

Article Drug pipeline

Translating ASCO Insights Into Action: A Payer’s Guide to What’s Next in Oncology

By Laura R. Bobolts